Related Experiment Videos
Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis
Vassilis Poulakis1, Philipp Dahm, Ulrich Witzsch
1Department of Urology and Paediatric Urology, Krankenhaus Nordwest, Teaching Hospital of the Johann-Wolfgang-Goethe-University Frankfurt, Frankfurt/Main, Germany. Poulakis@em.uni-frankfurt.de
BJU International
|June 26, 2004
Summary
Transurethral electrovaporization (TUEVP) and transurethral resection of the prostate (TURP) offer similar symptom relief for benign prostatic hyperplasia (BPH). TUEVP shows advantages in reduced bleeding and shorter hospital stays, while TURP has lower risks of retention and re-operation.
Area of Science:
- Urology
- Surgical Innovation
- Evidence-Based Medicine
Background:
- Benign prostatic hyperplasia (BPH) commonly causes symptomatic bladder outlet obstruction.
- Transurethral resection of the prostate (TURP) is a traditional treatment, while transurethral electrovaporization (TUEVP) is an alternative technique.
Purpose of the Study:
- To compare the effectiveness and safety of TUEVP versus TURP for BPH-related bladder outlet obstruction.
Main Methods:
- Systematic review and meta-analysis of 20 randomized controlled trials comparing TUEVP and TURP.
- Primary endpoints: symptom scores and peak urinary flow rates.
- Secondary endpoints: transfusion, operative time, catheterization, adverse events, hospital stay, re-operation, and sexual dysfunction.
Main Results:
- No significant difference in symptom scores or peak urinary flow rates between TUEVP and TURP after one year.
- TUEVP demonstrated significantly lower transfusion requirements, shorter catheterization duration, and reduced hospital stay.
- TURP was associated with a lower incidence of post-operative urinary retention and re-operation.
Conclusions:
- Both TUEVP and TURP provide comparable improvements in urinary flow and symptom scores for BPH.
- Each procedure has distinct advantages regarding secondary outcomes.
- Further high-quality, multicenter trials with longer follow-up are needed to clarify the role of TUEVP in BPH management.